CHEK2

The CHEK2 gene, located on chromosome 22q12.1, encodes checkpoint kinase 2, a serine/threonine kinase critical for maintaining genomic stability and regulating cell cycle checkpoints. 

Activated in response to DNA damage, CHEK2 plays a vital role in DNA repair by phosphorylating key proteins like p53 and BRCA1. This activation halts cell cycle progression, allowing for DNA repair or triggering apoptosis if the damage is irreparable. 

Mutations in CHEK2, such as the common I157T and c.1100delC variants, are linked to various cancers, including breast, prostate, and colorectal cancers, underscoring its significance in tumor suppression and the importance of genetic counseling for individuals with CHEK2 alterations.

What is the CHEK2 Gene and Enzyme? [3., 6.] 

The CHEK2 gene encodes a cell cycle checkpoint regulator and tumor suppressor involved in the DNA damage response. 

Located on chromosome 22q12.1, the CHEK2 protein is activated upon DNA damage, leading to cell cycle arrest by inhibiting replication enzymes and stabilizing the tumor suppressor protein p53. 

This protein interacts with BRCA1, enhancing its role in DNA repair and cell survival. 

Mutations in CHEK2 are linked to various cancers, including breast, prostate, and thyroid, and contribute to conditions like Li-Fraumeni syndrome. 

CHEK2 mutations can be truncating or missense, impacting its function in cell cycle regulation and DNA repair.

The CHEK2 Gene in Health and Disease

Breast Cancer [1., 2.]

Mutations in the CHEK2 gene, such as c.1100delC, are associated with an increased risk of breast cancer in women. These mutations lead to a truncated and unstable CHEK2 protein, impairing its tumor suppressor function.

Male Breast Cancer [1.] 

Similar to its role in female breast cancer, CHEK2 mutations also increase the risk of breast cancer in men. The gene's function in DNA repair and cell cycle control is crucial for preventing tumor development.

Colorectal Cancer [4.] 

Some CHEK2 mutations are linked to an elevated risk of colorectal cancer. The impaired DNA repair mechanisms due to defective CHEK2 protein contribute to the development of colorectal tumors.

One study concludes that the CHEK2 I157T mutation is associated with an increased risk of CRC, whereas truncating mutations do not significantly affect CRC risk. [4.] 

Prostate Cancer [2.] 

Mutations in CHEK2, such as I157T, are associated with a higher risk of prostate cancer. The gene's role in maintaining genomic stability is critical for preventing prostate cancer.

Thyroid Cancer [2.]

CHEK2 mutations are associated with an increased risk of thyroid cancer. The gene's tumor suppressor function is essential for preventing thyroid tumorigenesis.

Kidney Cancer [2.] 

The I157T variant of CHEK2 has been linked to an increased risk of kidney cancer. The mutation disrupts the protein's ability to interact with other key proteins involved in DNA repair and cell cycle regulation.

Li-Fraumeni Syndrome (LFS)

Li-Fraumeni Syndrome (LFS) is a rare autosomal dominant cancer syndrome predisposing individuals to a variety of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. [8.]

While CHEK2 mutations have been associated with Li-Fraumeni syndrome, clinical consensus among experts disagrees with this association. [7.] 

Specific Genetic Alterations in the CHEK2 Gene

The gene for the CHEK2 protein may contain alterations or mutations that cause increase or decrease of function of the CHEK2 protein.  

Testing for genetic alterations in the form of SNPs is increasingly available and can shed light on an individual’s potential for health and disease.  

What is a SNP?

A SNP, or single nucleotide polymorphism, refers to a variation at a single position in a gene along its DNA sequence.  A gene encodes a protein, so an alteration in that gene programs the production of an altered protein.  

As a type of protein with great functionality in human health, alterations in genes for enzymes may confer a difference in function of that enzyme.  The function of that enzyme may be increased or decreased, depending on the altered protein produced.  

SNPs are the most common type of genetic variation in humans and can occur throughout the genome, influencing traits, susceptibility to diseases, and response to medications.

The completion of the Human Genome Project has significantly expanded opportunities for genetic testing by providing a comprehensive map of the human genome that facilitates the identification of genetic variations associated with various health conditions, including identifying SNPs that may cause alterations in protein structure and function.  

Genetic testing for SNPs enables the identification of alterations in genes, shedding light on their implications in health and disease susceptibility.

Specific SNPs Associated with  the CHEK2 Gene

c.1100delC [5.] 

The CHEK2 1100delC mutation is a truncating variant known to significantly increase the risk of several cancers, particularly breast and prostate cancers. 

This mutation is clinically significant due to its association with higher cancer susceptibility, making it an important marker in genetic screenings and risk assessments for individuals with family histories of breast and prostate cancers.

I157T (c.470T>C) [2.] 

The I157T variant in the CHEK2 gene is considered a lower-risk pathogenic variant. 

It has a reduced association with breast cancer (OR, 0.66) compared to other CHEK2 PVs and shows no significant link to non-breast cancers such as colorectal, kidney, or thyroid cancers. 

However, it is associated with a higher frequency of bilateral breast cancer (OR, 1.52) compared to the wild-type CHEK2. This attenuated risk profile suggests that I157T should be considered separately in genetic counseling and clinical management.

Laboratory Testing for CHEK2

Genetic testing for single nucleotide polymorphisms (SNPs) typically involves obtaining a sample of DNA which can be extracted from blood, saliva, or cheek swabs. 

The sample may be taken in a lab, in the case of a blood sample.  Alternatively, a saliva or cheek swab sample may be taken from the comfort of home.  

Test Preparation

Prior to undergoing genetic testing, it's important to consult with a healthcare provider or genetic counselor to understand the purpose, potential outcomes, and implications of the test.  This consultation may involve discussing medical history, family history, and any specific concerns or questions. 

Additionally, individuals may be advised to refrain from eating, drinking, or chewing gum for a short period before providing a sample to ensure the accuracy of the test results.  Following sample collection, the DNA is processed in a laboratory where it undergoes analysis to identify specific genetic variations or SNPs. 

Once the testing is complete, individuals will typically receive their results along with interpretation and recommendations from a healthcare professional. 

It's crucial to approach genetic testing with proper understanding and consideration of its implications for one's health and well-being.

Patient-Centric Approaches

A patient-centered approach to SNP genetic testing emphasizes individualized medicine, tailoring healthcare decisions and interventions based on an individual's unique genetic makeup.

When that is combined with the individual’s health status and health history, preferences, and values, a truly individualized plan for care is possible. 

By integrating SNP testing into clinical practice, healthcare providers can offer personalized risk assessment, disease prevention strategies, and treatment plans that optimize patient outcomes and well-being. 

Genetic testing empowers a deeper understanding of genetic factors contributing to disease susceptibility, drug response variability, and overall health, empowering patients to actively participate in their care decisions. 

Furthermore, individualized medicine recognizes the importance of considering socioeconomic, cultural, and environmental factors alongside genetic information to deliver holistic and culturally sensitive care that aligns with patients' goals and preferences. 

Through collaborative decision-making and shared decision-making processes, patients and providers can make informed choices about SNP testing, treatment options, and lifestyle modifications, promoting patient autonomy, engagement, and satisfaction in their healthcare journey.

Genetic Panels and Combinations

Integrating multiple biomarkers into panels or combinations enhances the predictive power and clinical utility of pharmacogenomic testing. Biomarker panels comprising a variety of transporter proteins and enzymes including drug metabolizing enzymes offer comprehensive insights into individual drug response variability and treatment outcomes. 

Combining genetic SNP testing associated with drug transport, metabolism, and pharmacodynamics enables personalized medicine approaches tailored to individual patient characteristics and genetic profiles.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.